ArticleFrontiers in surgery2025
Artificial intelligence prediction of nonenhancing brain tumor malignancy based on
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-timeFrontiers in oncology · 2026Article
- Clinical application of confocal laser endomicroscopy in neurosurgery: a scoping review.Frontiers in surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although nonenhancing tumors are often thought to be lower grade, malignant regions can be missed on conventional magnetic resonance imaging. Fluorescein-based confocal laser endomicroscopy (CLE) enables real-time, cellular-resolution imaging of brain tissue during tumor resection. It is particularly valuable for evaluating nonenhancing brain tumors. However, CLE interpretation remains subjective. Although CLE has high sensitivity, it is less specific than standard histology. Existing artificial intelligence (AI) models process CLE images as independent frames, neglecting the temporal context that human experts use during interpretation. Methods: A novel sequence-based deep learning model was developed to classify tumor grade on the basis of CLE image sequences, mimicking the visual reasoning process of expert neuropathologists. CLE images were collected from 16 patients with nonenhancing brain tumors. Each sequence was labeled as high grade or low grade based on neuropathologist interpretation, blinded to final histopathology findings. Visual features were extracted using pretrained backbones (vision transformer, VGG16, ResNet50), followed by temporal modeling with a transformer encoder and temporal convolution. This model was compared with conventional frame-based classification across 3 random train-test splits. Results: The dataset included 105 CLE sequences (3,173 images, 40 regions of interest). The sequence-based model achieved top-1 classification accuracies of 93% (vision transformer), 88% (VGG16), 74% (ResNet50), and 67% (Inception-ResNet-V2), outperforming corresponding frame-based models (78%, 74%, 55%, and 50%, respectively). Diagnostic performance was comparable to expert neuropathologist interpretation (87%). The model demonstrated robustness in artifact-affected sequences and improved interpretability by incorporating temporal progression. Conclusions: AI models that integrate both visual and temporal information from CLE digital imaging sequences can effectively classify brain tumor grade with accuracy comparable to that of expert neuropathologists, outperforming frame-based models. Such a system reduces interpretive subjectivity and holds promise as an intraoperative decision CLE support tool for nonenhancing brain tumor resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.